Intratio
Loading...
Skip to main content
Stock comparison · Signal date 2026-11-06

OBX vs SGMT: stock comparison and AI forecast

Obsidian Therapeutics, Inc. (OBX) and Sagimet Biosciences Inc. (SGMT) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market

Share
Nasdaq · Pharmaceutical Preparations

OBX Obsidian Therapeutics, Inc.

Market Cap
$593M
P/E Ratio
–
Size
small-cap
AI Forecast
Full analysis →
Nasdaq · Pharmaceutical Preparations

SGMT Sagimet Biosciences Inc.

Market Cap
$646M
P/E Ratio
–
Size
small-cap
AI Forecast
Full analysis →
Model output

Which one does the AI model favor?

Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.

OBX · SGMT

Key facts

  • OBX and SGMT have similar market capitalizations ($593M and $646M).
  • Both companies share the SEC industry classification Pharmaceutical Preparations.
Fundamentals

Fundamentals side by side

Trailing twelve months.

Valuation & Market

MetricOBXSGMT
Market Cap$593M$646M
EPS–$-1.52

Financial Health

MetricOBXSGMT
Current Ratio2.30x45.02x
Working Capital$26M$239M

Cash Flow

MetricOBXSGMT
Operating Cash Flow–-$42M

Income Statement

MetricOBXSGMT
Operating Income–-$53M
R&D Expense–$35M

Dividend & Shareholder Information

MetricOBXSGMT
Shares Outstanding62M71M
FAQ

OBX vs SGMT: stock comparison and AI forecast

Which is bigger, OBX or SGMT?

OBX and SGMT have similar market capitalizations ($593M and $646M).

Which one does Intratio's AI model rank higher, OBX or SGMT?

Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.

Compare

More comparisons

This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.